Business Wire
BusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex TimesBusinessModerna shares jump 160%, dealing a roughly $5 billion hit to short sellersThe Apex TimesBusinessModerna and Merck tout a personalized mRNA approach that aims to train immunity against recurring melanomaThe Apex TimesBusinessTesla rises about 3% and Rivian jumps about 4%, as EV shares outperform legacy automakers after a Treasury Department noticeThe Apex TimesBusinessMSD and Moderna face a pivotal market test after Phase III melanoma data lifts hopes for a personalized cancer vaccineThe Apex TimesBusinessModerna and Merck spotlight melanoma recurrence-reduction in personalized mRNA vaccine studyThe Apex TimesBusinessPfizer tests a new angle on obesity care with berobenatide, aiming for a less-frequent optionThe Apex TimesBusinessEx–Meta child-safety engineer tells jury his family was targeted on InstagramThe Apex TimesBusinessTesla teases Cybercab launch event, raising hopes of a fresh catalyst for TSLAThe Apex TimesBusinessBerkshire’s cash pile shrank to $365.5B, and buybacks gave way to stock buying again under Greg AbelThe Apex TimesBusinessModerna and Merck move a step closer to a first mRNA cancer vaccine after a reported Phase 3 winThe Apex TimesBusinessModerna shares jump after late-stage melanoma results renew focus on its cancer pipelineThe Apex TimesBusinessModerna shares surge after Phase 3 cancer results, sending short sellers deeper into lossesThe Apex Times
Back to front
Intel and AMD slide about 4% while NVIDIA holds steady as chip stocks drag
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 11:49 AM EDT

Intel and AMD slide about 4% while NVIDIA holds steady as chip stocks drag

Even as bond yields eased and the broader market turned green, semiconductor shares moved unevenly, with Intel and AMD falling while NVIDIA stayed flat, underscoring how investors are still trading the sector stock-by-stock.

2 min readEditor-approved Apex article

Chip stocks sold off sharply on Aug. 19, with investors appearing to look past a late improvement in rates and market breadth. According to the market report, Intel and AMD fell roughly 4% each, while NVIDIA was described as unchanged, creating a split in how investors priced near-term outlook across large-cap semiconductors.

The move came despite a broader attempt at relief elsewhere in markets. The report said bond yields fell and major indexes turned green, conditions that often support growth and risk assets when financing costs cool. Even with that backdrop, semiconductor shares did not follow the same pattern, suggesting company-specific concerns or positioning outweighed the rate tailwind.

Within the sector, the biggest headline was dispersion. Intel and AMD were each highlighted as declining meaningfully in the session, while NVIDIA was singled out as holding completely flat. That kind of divergence can reflect differences in investor expectations around demand, margins, product cycles, or how each stock is positioned relative to upcoming catalysts.

The report framed the action as a “chip selloff” that “defies” the perceived bond-yield relief. In other words, even though yields were lower, the market still punished parts of the group. The absence of a similar decline for NVIDIA was presented as the standout contrast, pointing to a possible quality or momentum effect rather than a uniform sector repricing.

For AMD, the move is notable because the company’s results and outlook are typically closely tied to the performance of its client and data center platforms, including its data center accelerators and CPU roadmap. The immediate weakness in the stock, in this account, does not establish a fundamental change by itself, but it does indicate that at least some investors were willing to reduce exposure even when rates eased.

Intel’s trading performance also matters for the same reason. Intel has been working through a multi-year repositioning of its manufacturing and product strategy, and its share price is often sensitive to investor confidence about execution timelines. The roughly 4% decline cited in the report suggests the session’s selling was not limited to “beta” technology exposure but extended to the more execution-sensitive names as well.

Still, the report did not provide additional detail on what specifically drove orders or headlines for each stock on the day. It did not cite particular earnings updates, guidance changes, analyst revisions, or company announcements in the description provided, so readers should treat the move as a market snapshot rather than a confirmed catalyst-driven development.

Why It Matters

  • The uneven performance suggests investors were differentiating among chip names even as rates eased, which can be a sign of shifting expectations or positioning.
  • A sector pullback that does not lift all leaders can complicate index-level interpretations of “risk-on” conditions.
  • For AMD and Intel, the cited declines highlight how quickly sentiment can turn even without a disclosed catalyst in the report’s description.
  • Traders and investors may look next to any company-specific indicates, such as guidance commentary or analyst changes, to explain the dispersion.

Sources

Key Facts

  • On Aug. 19, Intel and AMD were reported down about 4% each in the session.
  • NVIDIA was reported as unchanged, standing out against the broader chip selloff.
  • The report said bond yields fell and the broader market turned green at the same time.
  • Despite that backdrop, semiconductor shares still declined, indicating a stock-by-stock divergence rather than a uniform rate-driven move.

Technology Related